We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.63 | -1.08% | 57.63 | 57.63 | 57.95 | 57.96 | 57.47 | 57.95 | 1,943,039 | 00:58:18 |
From Sep 2019 to Sep 2024
By Michael Dabaie
Lexicon Pharmaceuticals Inc. (LXRX) was up 7.2% to $6.39 in heavier-than-average trading Monday.
The company said Friday that the European Commission granted marketing authorization for Zynquista, which was developed by Sanofi (SNY) and Lexicon. Zynquista is now approved in the European Union for treatment of adults with type 1 diabetes.
Lexicon said Zynquista also is currently being evaluated in a program of 11 clinical trials in adults with type 2 diabetes, including two trials in people living with type 2 diabetes and renal impairment, and two large cardiovascular outcomes trials.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 29, 2019 11:25 ET (15:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
